Aquestive Therapeutics vs Ocular Therapeutix
AQST and OCUL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and OCUL compare
Ocular Therapeutix is the larger company, worth 2.8 times as much as Aquestive Therapeutics ($1.3B against $464M).
Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus −8.1% for Ocular Therapeutix).
Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −579% at Ocular Therapeutix.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | OCUL |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $1.3B |
| Share price | $3.70 | $6.02 |
| Change, 1 year | −31.4% | −46.7% |
| Change, 5 years | −41.9% | −8.0% |
| Beta (5Y) | 1.20 | 1.53 |
| Employees | 147 | 325 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.6× (better) | 25.4× |
| P/B | – | 2.5× |
| FCF yield | −9.9% (better) | −19.3% |
| Fair value | – | $5.44 |
| Margin of safety | – | −10.6% |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | −8.1% |
| Revenue growth, 5Y average | −0.58% | 24.4% (better) |
| Profitability | ||
| Gross margin | 67.0% | 87.1% (better) |
| Operating margin | −97.5% (better) | −603% |
| Net margin | −145% (better) | −579% |
| FCF margin | −85.0% (better) | −490% |
| Return on equity | – | −73.0% |
| Financial health | ||
| Debt / equity | – | 0.14 |
| Interest coverage | −4.7× (better) | −27.5× |
| Current ratio | 7.19 | 13.11 (better) |
| Altman Z-score | −3.57 | 2.08 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 94.4% |
| Held by insiders | 3.2% | 2.9% |
| Insider net buying, 12 months | −$2.3M (better) | −$2.5M |
| Short interest, % of float | 24.1% | 13.6% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- OCUL stock overview
- OCUL income statement
- OCUL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.